RHO and neoplasm: The expression of PGAM5 that dephosphorylates and activates ASK1 MAP3K [144] and prolongs survival of tumor cells in hepatocellular carcinoma (HCC) [145], and PLXNB2, an activator of the GTPase Rho [56], promoting ovarian cancer cell proliferation and invasion [57] and prostate tumor growth [58], as well as ICAM1, which activates Rho [54] and which increased metastasis in pancreatic ductal adenocarcinoma [55], were reduced (5- and 16-fold).